Andreas Pahl

Company: Heidelberg Pharma

Job title: Chief Scientific Officer & Executive Vice President & Member of the Executive Board

Seminars:

Antibody Targeted Amanitin Conjugates (ATAC) 5:15 pm

• Evaluate Antigen-Targeted Amanitin-Conjugates (ATACs); A new class of ADCs using the payload Amanitin • Understand how this payload introduces a novel mode of action into oncology therapy, the inhibition of RNA polymerase II • Learn more about this technology platform that includes Amanitin supply, site specific conjugation, demonstrated safety profile and biomarker • Gain…Read more

day: Day One